---
title: "Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286420726.md"
description: "Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News"
datetime: "2026-05-14T04:55:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286420726.md)
  - [en](https://longbridge.com/en/news/286420726.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286420726.md)
---

# Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | CURX Stock News

### Related Stocks

- [CURX.US](https://longbridge.com/en/quote/CURX.US.md)

## Related News & Research

- [Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295957896.md)
- [INBS: Revenue up 38% to $4.2M, gross margin 48.63%, FDA submission on track for late 2026](https://longbridge.com/en/news/296357255.md)
- [Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorder](https://longbridge.com/en/news/296491293.md)
- [OTLK: FDA approval and launch plans for LYTENAVA drive growth prospects amid improved financials](https://longbridge.com/en/news/295929118.md)
- [XSPRAY: FDA requests more manufacturing data for Dasynoc; resubmission planned for 2026](https://longbridge.com/en/news/296372083.md)